GSK camlipixant headline data disappoints; asset termination is a slight negative

Overview

This report is a company update from Deutsche Bank on GSK, focusing on the headline clinical results for the chronic cough pipeline asset camlipixant. The report notes that GSK failed to deliver the expected positive pipeline news: CALM-1 met its endpoint but CALM-2 failed, resulting in the termination of camlipixant's development. Analysts characterize the event as clearly slightly negative, while the rating remains Hold.

Core views

The core view is that camlipixant's failure weakens GSK's credibility in using its pipeline to bridge its mid-term growth gap. Although this asset was not the largest source of value in Deutsche Bank's model, it still contributed about 74p/share of NPV and was seen as part of helping the company 'bridge' toward its mid-term revenue target of more than £40bn. Following the event, Deutsche Bank plans to revisit its model in conjunction with Q2 results and the July 28 'accelerate growth' event.

Analysis framework

The report mainly uses event-driven interpretation of clinical results, pipeline NPV breakdown, and comparisons with peer and same-mechanism assets. The analysis focuses on the success and failure of CALM-1 and CALM-2, the clinical landscape for chronic cough P2X3, differences in 2031E sales expectations, and the 12-month valuation framework underpinning GSK's overall target price.

Methodology notes

• Valuation methodsNPV breakdown

  Net present value of pipeline assets

  The report includes camlipixant in GSK Group's NPV at about 74p/share, with group NPV at about 2396p/share, assuming peak sales of about £0.8bn in 2037E.

• Valuation methods12-month P/E target price

  Target price methodology

  The report explains that the stock target price is based on a 12-month P/E, and therefore usually differs from the NPV of an individual asset or the group's NPV.

• Clinical analysisCross-sectional clinical comparison of P2X3 chronic cough

  Comparison of same-mechanism and adjacent-mechanism assets

  The report lists chronic cough clinical programs such as Gefapixant, Camlipixant, Sivopixant, and Eliapixant to assess the competitive landscape in terms of efficacy, AEs, taste disturbance, and discontinuation rates.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• GSK.L

  Primary covered target in the report

  Strengths

  The pharmaceuticals business and other R&D pipeline assets still provide support, and Deutsche Bank maintains a Hold rating.

  Weaknesses

  The termination of camlipixant means pipeline news flow is below expectations and increases pressure on the credibility of mid-term growth targets.

  Comparison

  The target price of GBP 1,950.00 is close to the price of GBP 1,956.00 on 16 Jul 2026, reflecting a lack of clear upside on a 12-month view.

  Risks

  Further pipeline failures, Q2 results below expectations, or the growth event failing to explain the path to bridging the >£40bn revenue target.

• camlipixant (BLU-5937)

  GSK chronic cough P2X3 pipeline asset

  Strengths

  CALM-1 met its endpoint, and the asset previously still carried about 74p/share of NPV in the model.

  Weaknesses

  CALM-2 failed, leading to termination of the asset and removing the positive catalyst from the investment thesis.

  Comparison

  There are already assets such as Gefapixant in the P2X3 chronic cough space, but the field still faces challenges in clinical efficacy, AEs, and regulatory acceptability.

  Risks

  Termination of development means the related sales, NPV, and pipeline bridging contribution need to be reduced or removed.

Key data

• RatingHoldDeutsche Bank maintains a neutral rating on GSK.
• Target priceGBP 1,950.00The report table lists the Price Target as GBP 1,950.00.
• Current priceGBP 1,956.00 at 16 Jul 2026The report table lists the price on 16 Jul 2026 as GBP 1,956.00.
• camlipixant trial resultsCALM-1 hit; CALM-2 missedThe two replicate headline trials produced divergent results, and the asset will be terminated.
• camlipixant 2031E sales expectationDB/consensus approximately £0.5bnThe report says Deutsche Bank and consensus are both at about £0.5bn for 2031E and will revisit this alongside Q2 and the July 28 event.
• camlipixant NPV74p/shareThis asset is included in GSK Group's NPV.
• GSK Group NPV2396p/shareDeutsche Bank includes camlipixant in the group NPV.
• Peak sales assumption£0.8bn in 2037EUsed for camlipixant NPV valuation.
• 2031E revenue bridging gapmanagement >£40bn vs DB/consensus £35bn/£37bnThe report believes the asset failure extends the gap between mid-term guidance and market expectations.

Impact & implications

In terms of investment implications, camlipixant's failure is not a single decisive event, but it does weaken the narrative around GSK's pipeline delivery and mid-term growth bridge. Near-term focus shifts to Q2 results, the July 28 growth event, and how management explains the gap between its revenue target and consensus expectations.

Risks

• The termination of camlipixant increases pressure on GSK's mid-term growth bridge.
• If Q2 results or the July 28 growth event cannot provide new credible sources of growth, the market may continue to question the revenue target of over £40bn.
• The chronic cough P2X3 mechanism faces uncertainty in efficacy, taste disturbance, AEs, and regulatory acceptance.
• The target price is close to the current price, leaving limited near-term upside for the stock.
• The report discloses that Deutsche Bank and GSK have multiple investment banking or service relationships, and investors should read the relevant conflict disclosures.

What to watch

• GSK's Q2 results release and management's explanation of the modeling impact from the termination of camlipixant.
• The explanation at the July 28, 2026 'accelerate growth' event of how the mid-term revenue target will be bridged.
• Whether Deutsche Bank lowers its assumptions for camlipixant-related NPV, 2031E sales, and group valuation.
• Other GSK pipeline news flow, especially R&D catalysts that could offset the failure of the chronic cough asset.
• Efficacy and safety data from other P2X3 or non-P2X3 mechanism assets in the chronic cough clinical landscape.